Skip to main content

Advertisement

Table 4 KRAS genotype frequencies and HR status and HER2 status according to HRT stratification

From: KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study

Study population Genotype Frequency p Frequency p p
   N(%) value N(%) value
   HR+ HR-   HER2+ HER2-  
All wild(TT) 363(82.9) 69(83.1) 0.955 49(77.8) 372(84.0) 0.218
  variable(TG/GG) 75(17.1) 14(16.9)   14(22.2) 71(16.0)  
Nonusers: HRT < 1 year wild(TT) variable(TG/GG) 250(81.7) 56(18.3) 52(85.2) 9(14.8) 0.508 41(83.7) 8(16.3) 255(82.8) 53(17.2) 0.879
Users: HRT 1 years wild(TT) 113(85.6) 17(77.3) 0.318 8(57.1) 117(86.7) 0.004
  variable(TG/GG) 19(14.4) 5(22.7)   6(42.9) 18(13.3)  
  1. Statistically significant results are shown in bold